Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Holding BPMC?
Track your performance easily
BPMC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$65.68 - $121.90
Previous Close$94.81
Volume566.22K
Average Volume (3M)620.10K
Market Cap
$6.01B
Enterprise Value$6.01B
Total Cash (Recent Filing)$734.17M
Total Debt (Recent Filing)$732.70M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Feb 13, 2025EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding63,525,838
10 Day Avg. Volume603,308
30 Day Avg. Volume620,097
Standard Deviation0.14
R-Squared0.05
Alpha0.00582
Financial Highlights & Ratios
Price to Book (P/B)19.23
Price to Sales (P/S)13.83
Price to Cash Flow (P/CF)-110.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.83
Enterprise Value/Gross Profit24.95
Enterprise Value/Ebitda-56.59
Forecast
1Y Price Target
$122.85Price Target Upside29.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Blueprint Medicines News
Bulls Say, Bears Say
Bulls Say
Product Efficacy And SafetyBLU-808 is emerging as a potential best-in-class treatment for mast cell disorders, particularly chronic urticaria, with a novel small molecule TKI approach.
Revenue GrowthAyvakit's strong performance and increased guidance indicate the 'short the launch' thesis is obsolete, providing a solid foundation for the stock's setup through 2025.
Strategic PartnershipsBPMC could be seen as an attractive target for strategic partnerships, which could boost shares due to its strong revenue contributor Ayvakit and potential in larger mast cell markets.
Bears Say
Market CompetitionThe competitive landscape includes several companies developing similar therapies, which could impact Blueprint Medicines' market position.
Product Side EffectsBlueprint's avapritinib has shown higher rates of periorbital edema and cognitive side effects in ASM.
Revenue Growth OutlookThe price target was reduced to $89 from $97 due to a revised outlook on revenue growth.
---
Ownership Overview
1.56% Insiders
43.72% Mutual Funds
23.35% Other Institutional Investors
13.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $65.68 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is Feb 13, 2025 which is in 84 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Oct 30, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$0.961 by $0.071.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -$0.7.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,525,837 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.89 in its last earnings report, beating expectations of -$0.961. Following the earnings report the stock price went up 7.002%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 81M.
---
Blueprint Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$122.85 (29.57% Upside)
$122.85 (29.57% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 80%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $324.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.91%
12-Months-Change
Fundamentals
Return on Equity
-49.66%
Trailing 12-Months
Asset Growth
8.54%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q3 2024
0:00 / 0:00
---
BPMC Stock 12 Month Forecast
Average Price Target
$122.85
▲(29.57% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+34.84%
reiterated a buy rating 7 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +34.84% per trade.
---